ReviewEcancermedicalscience2015
Anti-androgenic effects of flavonols in prostate cancer.
Review in Ecancermedicalscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Association of finasteride with prostate cancer: A systematic review and meta-analysis.Medicine · 2020Pooled it
- Green chemistry for prostate health: exploring nature's toolbox against cancer, inflammation, and hyperplasia.Molecular diversity · 2026Review
- Myricetin alleviates testosterone-induced benign prostatic hyperplasia by attenuating inflammation, oxidative stress, apoptosis and androgen signaling.Scientific reports · 2026Article
- Prostate Cancer, JAK/STAT3 Dysregulation, and Flavonoids: Is There a Possible Link?International journal of molecular sciences · 2026Review
- Red Currant (Plants (Basel, Switzerland) · 2025Article
- The Pros and Cons of Estrogens in Prostate Cancer: An Update with a Focus on Phytoestrogens.Biomedicines · 2024Review
- Flavonoid Myricetin as Potent Anticancer Agent: A Possibility towards Development of Potential Anticancer Nutraceuticals.Chinese journal of integrative medicine · 2024Review
- In vitro combination effects of plant-derived quercetin with synthetic bicalutamide on prostate cancer and normal cell lines: in silico comparison.In silico pharmacology · 2024Article
- Phytochemical-Based Study of Ethanolic Extract ofACS omega · 2023Article
- Natural flavonols: actions, mechanisms, and potential therapeutic utility for various diseases.Beni-Suef University journal of basic and applied sciences · 2023Review
- Evaluation of apoptotic effects of mPEG-b-PLGA coated iron oxide nanoparticles as a eupatorin carrier on DU-145 and LNCaP human prostate cancer cell lines.Journal of pharmaceutical analysis · 2021Article
- Dietary flavonoid myricetin inhibits invasion and migration of radioresistant lung cancer cells (A549-IR) by suppressing MMP-2 and MMP-9 expressions through inhibition of the FAK-ERK signaling pathway.Food science & nutrition · 2020Article
- Short-term exposure to chrysin promotes proliferative responses in the ventral male prostate and female prostate of adult gerbils.International journal of experimental pathology · 2019Article
- Molecular Mechanisms and Bioavailability of Polyphenols in Prostate Cancer.International journal of molecular sciences · 2019Review
- Androgen receptor and soy isoflavones in prostate cancer.Molecular and clinical oncology · 2019Review
- Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways.World journal of surgical oncology · 2018Article
- Phyto-polyphenols as potential inhibitors of breast cancer metastasis.Molecular medicine (Cambridge, Mass.) · 2018Review
- Preparation and Antioxidant Activity of Ethyl-Linked Anthocyanin-Flavanol Pigments from Model Wine Solutions.Molecules (Basel, Switzerland) · 2018Article
- Quercetin Targets hnRNPA1 to Overcome Enzalutamide Resistance in Prostate Cancer Cells.Molecular cancer therapeutics · 2017Article
- Myricetin induces apoptosis and enhances chemosensitivity in ovarian cancer cells.Oncology letters · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dietary-derived agents, such as the flavonoids, are of particular interest for prostate cancer (PCa) chemoprevention as they may offer a favourable safety and side-effect profile. An agent that demonstrates action on the androgen receptor (AR) axis may have value for preventing or treating castrate-resistant PCa. Four main flavonols - quercetin, myricetin, kaempferol, and fisetin - have been demonstrated in laboratory studies to have chemopreventive action in both castrate-resistant and castrate-sensitive PCa models. Mechanisms of flavonol action on the AR axis in PCa have been proposed to be inhibition of the 5α-reductase enzymes, direct androgen competition, suppression of the AR complex and transactivation by coregulators such as c-Jun, Sp1, and the PI3K/Akt pathway. It is, however, still unclear with current levels of evidence whether AR axis-mediated effects can fully account for the flavonols' chemopreventive action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.